(Q34392656)

1 August 2017

1 reference

title

Long-acting inhaled beta(2)-agonist therapy in asthma (English)

1 reference

1 August 2017

0 references

J C Kips

1

1 reference

PubMed ID

11587972

1 August 2017

R A Pauwels

series ordinal

2

1 reference

PubMed ID

11587972

1 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

American Journal of Respiratory and Critical Care Medicine

1 August 2017

1 reference

1 August 2017

164

1 reference

1 August 2017

923-932

1 reference

1 August 2017

6

1 reference

Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients

1 August 2017

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Why are long-acting beta-adrenoceptor agonists long-acting?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Potential masking effects of salmeterol on airway inflammation in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Regular inhaled beta agonist in asthma: effects on exacerbations and lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Long-acting beta(2)-agonists in management of childhood asthma: A critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in atopic asthmatics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Inhibitory effects of formoterol on platelet-activating factor induced eosinophil chemotaxis and degranulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Beta-adrenergic receptors and their regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Molecular mechanisms of membrane receptor desensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Role of cyclo-oxygenase-2 induction in interleukin-1beta induced attenuation of cultured human airway smooth muscle cell cyclic AMP generation in response to isoprenaline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Mechanisms of acute desensitization of the beta2AR-adenylyl cyclase pathway in human airway smooth muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Mechanisms of impaired beta-adrenoceptor-induced airway relaxation by interleukin-1beta in vivo in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Interactions of glucocorticoids and beta 2-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Regulation of β-Adrenergic Receptors by Steroid Hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Salmeterol tachyphylaxis in steroid treated asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Transcription factors and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

The interaction between salmeterol and beta 2-adrenoceptor agonists with higher efficacy on guinea-pig trachea and human bronchus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Correlation of cyclic AMP accumulation and relaxant actions of salmeterol and salbutamol in bovine tracheal smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Effects of a range of beta2 adrenoceptor agonists on changes in intracellular cyclic AMP and on cyclic AMP driven gene expression in cultured human airway smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Estimation of the efficacy and affinity of the β2-adrenoceptor agonist salmeterol in guinea-pig trachea

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Salmeterol-induced desensitization, internalization and phosphorylation of the human beta2-adrenoceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

A comparison of the efficacy of long-acting beta 2-agonists: eformoterol via Turbohaler and salmeterol via pressurized metered dose inhaler or Accuhaler, in mild to moderate asthmatics. Force Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Association of beta2-adrenergic receptor polymorphisms with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

The effects of beta 2-adrenoceptor agonists and a corticosteroid, budesonide, on the secretion of inflammatory mediators from monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Anti-inflammatory effect of beta 2-agonists: inhibition of TNF-alpha release from human mast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Salmeterol is a competitive antagonist at beta-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Evidence that the eosinophil is a cellular target for the inhibitory action of salmeterol on eosinophil recruitment in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Formoterol and salbutamol inhibit bradykinin- and histamine-induced airway microvascular leakage in guinea-pig

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Long Duration and High Potency of Antiexudative Effects of Formoterol in Guinea-Pig Tracheobronchial Airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

The effects of formoterol on plasma exudation produced by a localized acute inflammatory response to bradykinin in the tracheal mucosa of rats in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Duration of action of formoterol and salbutamol dry-powder inhalation in prevention of exercise-induced asthma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

beta2-adrenoceptor polymorphisms and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

β2-Adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma☆☆☆★★★

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

A growing coactivator network

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.164.6.2010107

10.1164/AJRCCM.164.6.2010107

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11587972